Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond
The model's full reasoning — Q1 2024 call → NOWe need to determine if management expresses clear conviction about a step-up ahead and grounds it in concrete things already in hand. The call discusses various aspects: sales growth, agent counts, investments, etc. Management gives guidance for 2024, but is there a clear statement of a step-up to a meaningfully higher level? They mention growth in agent counts, sales, premiums, but it seems like steady growth rather than a dramatic step-up. They also discuss investments in technology, but not necessarily a step-up. The tone is more about maintaining growth and addressing recent issues (short seller, DOJ). They mention "we continue to generate sustainable earnings growth" but not a step-up. They also discuss share repurchases and capital. The conviction about a step-up? They give guidance for 2024 with growth rates, but that's not necessarily a step-up beyond current trends. They also mention "we expect life premium revenue to grow between 4.5% and 5%" etc. That's steady. They also discuss agent count growth, but it's moderate. They also mention "we are actively evaluating the impact on AIL’s agent count and projected sales" due to recent events, so they are cautious. So no clear conviction about a step-up. They also don't ground in concrete things already in hand beyond current performance. They mention investments in technology, but that's not a step-up. So answer NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.